![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: a Phase 2 "Proxy" Study
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Ed Gane1,2, Christian Schwabe1, Michael Mader3, Vithika Suri2, Mary Donohue3, Mingjun Huang3, James Hui3, Joanna Yang3, Heather Robison3, David Apelian3, Hetal Kocinsky3
Affiliations: 1Auckland Clinical Studies Ltd, Grafton, New Zealand; 2Auckland City Hospital, Auckland, New Zealand; 3Achillion Pharmaceuticals, New Haven, CT, USA
![EASL1.gif](../images/043115/043115-7/EASL1.gif)
![EASL2.gif](../images/043115/043115-7/EASL2.gif)
![EASL3.gif](../images/043115/043115-7/EASL3.gif)
![EASL4.gif](../images/043115/043115-7/EASL4.gif)
![EASL5.gif](../images/043115/043115-7/EASL5.gif)
![EASL6.gif](../images/043115/043115-7/EASL6.gif)
![EASL7.gif](../images/043115/043115-7/EASL7.gif)
![EASL8.gif](../images/043115/043115-7/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|